Coral Laboratories has announced a key personnel change with the resignation of Mrs. Dhwani Desai from her position as Company Secretary and Compliance Officer. The resignation, submitted to pursue another career opportunity, will take effect from the closure of business hours on January 31, 2026.

Resignation Details

The pharmaceutical company informed BSE Limited on December 30, 2025, about Mrs. Desai's decision to step down from her role. The Board of Directors has accepted her resignation, and she will be relieved from all responsibilities associated with her position at the end of January 2026.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made through a formal communication to BSE Limited, where Coral Laboratories trades under scrip code 524506.

Key Personnel Impact

Following Mrs. Desai's resignation, she will also cease to function as Key Managerial Personnel of the company effective January 31, 2026. The resignation letter and complete details as required under SEBI regulations have been submitted to the stock exchange as part of the mandatory disclosure process.

Company Communication

The formal intimation was signed by Sushma Kadkade, Director and CFO of Coral Laboratories Limited, ensuring proper authorization and compliance with corporate governance requirements. The company has provided all necessary documentation to maintain transparency with stakeholders and regulatory authorities.

Coral Laboratories Limited , a pharmaceutical company, has announced a significant capacity expansion project at its Dehradun plant. The Board of Directors approved the expansion plan on October 13, 2025, aiming to triple the ointment manufacturing capacity to meet growing demand in domestic and international markets.

Expansion Details

The capacity expansion project involves the following key aspects:

Financial Implications and Strategy

The company plans to finance this ₹30 crore investment through a combination of bank overdraft facilities and internal accruals. This strategic move is expected to support Coral Laboratories' growth objectives in both domestic and international pharmaceutical markets.

Rationale Behind Expansion

According to the company's filing, the primary reasons for this capacity expansion are:

1. Meeting captive demand
2. Supporting sales growth in domestic and international markets
3. Overall business expansion

The current plant operates at approximately 80% capacity utilization, indicating a need for additional manufacturing capabilities to meet future demand.

Regulatory Compliance

Coral Laboratories has duly informed the BSE Limited about this development, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This capacity expansion represents a significant step for Coral Laboratories in strengthening its manufacturing capabilities and positioning itself for future growth in the pharmaceutical sector.